crisaborole

Targeted treatments for atopic dermatitisEmerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
New hope for eczemaThe US Food and Drug Administration (FDA) has announced its approval of a new, corticoid-sparing ointment to treat mild to moderate atopic dermatitis in pediatric patients aged 2 years and older.
FDA approves corticosteroid-sparing topical option for eczemaThe FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
January Clinical Considerations for NPs, PAsThis month, we take a look at when to use biologics, advances in pediatric Atopic Dermatitis (AD), and how Trump’s presidency might impact dermatology.